Korea To Reform Reimbursement Management To Cut Expenditure

To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.

Gangnam
Korea To Reallocate Resources Through Drug Re-evaluation • Source: Shutterstock

South Korea plans to conduct a re-evaluation of reimbursed drugs with a view to cutting their prices or delisting them from the national health insurance tariff if they fail to meet certain conditions, and also to lower prices of generics through regular comparisons with overseas prices.

Both moves are being mulled in an attempt to cut rising expenditure under the universal care system.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from South Korea

More from Asia